Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
VCYT Veracyte Inc
- Stocks
- Healthcare
- NASDAQ: VCYT
Price (delayed)
$30.76
Market cap
$2.41B
P/E Ratio
71.53
Dividend/share
N/A
EPS
$0.43
Enterprise value
$2.27B
Veracyte is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other
Highlights
Veracyte's net income has surged by 148% YoY and by 37% QoQ
The EPS has surged by 146% year-on-year and by 34% since the previous quarter
Key stats
What are the main financial stats of VCYT
Market
Valuations
Earnings
Shares outstanding
78.31M
Market cap
$2.41B
Enterprise value
$2.27B
Price to earnings (P/E)
71.53
Price to book (P/B)
2.01
Price to sales (P/S)
5.18
EV/EBIT
64.76
EV/EBITDA
36.04
EV/Sales
4.9
Revenue
$463.39M
Gross profit
$315.19M
Operating income
$23.7M
Net income
$33.05M
EBIT
$35.08M
EBITDA
$63.03M
Free cash flow
$78.45M
Per share
Balance sheet
Liquidity
EPS
$0.43
EPS diluted
$0.41
Free cash flow per share
$1.01
Book value per share
$15.33
Revenue per share
$5.94
TBVPS
$5.92
Total assets
$1.32B
Total liabilities
$120.48M
Debt
$50.5M
Equity
$1.19B
Working capital
$308.03M
Debt to equity
0.04
Current ratio
5.1
Quick ratio
4.56
Net debt/EBITDA
-2.18
Margins
Efficiency
Dividend
EBITDA margin
13.6%
Gross margin
68%
Net margin
7.1%
Operating margin
5.1%
Return on assets
2.6%
Return on equity
2.8%
Return on invested capital
23.7%
Return on capital employed
2.8%
Return on sales
7.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VCYT stock price
How has the Veracyte stock price performed over time
Intraday
3.53%
1 week
-1.79%
1 month
-3.27%
1 year
43.94%
YTD
-22.32%
QTD
3.74%
Financial performance
How have Veracyte's revenue and profit performed over time
Revenue
$463.39M
Gross profit
$315.19M
Operating income
$23.7M
Net income
$33.05M
Gross margin
68%
Net margin
7.1%
Veracyte's net income has surged by 148% YoY and by 37% QoQ
The net margin has soared by 139% YoY and by 31% from the previous quarter
The operating income has soared by 130% YoY and by 47% from the previous quarter
The operating margin has soared by 124% YoY and by 42% from the previous quarter
Price vs fundamentals
How does VCYT's price correlate with its fundamentals
Growth
What is Veracyte's growth rate over time
Valuation
What is Veracyte stock price valuation
P/E
71.53
P/B
2.01
P/S
5.18
EV/EBIT
64.76
EV/EBITDA
36.04
EV/Sales
4.9
The EPS has surged by 146% year-on-year and by 34% since the previous quarter
The P/B is 20% below the 5-year quarterly average of 2.5 and 4.3% below the last 4 quarters average of 2.1
The equity has grown by 7% YoY
The P/S is 47% below the 5-year quarterly average of 9.8 and 6% below the last 4 quarters average of 5.5
Veracyte's revenue has increased by 23% YoY and by 4% QoQ
Efficiency
How efficient is Veracyte business performance
The company's return on equity has surged by 144% YoY and by 33% QoQ
The ROA has soared by 144% YoY and by 37% from the previous quarter
The return on sales has surged by 140% year-on-year and by 31% since the previous quarter
VCYT's return on invested capital has surged by 122% year-on-year but it is down by 3.7% since the previous quarter
Dividends
What is VCYT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VCYT.
Financial health
How did Veracyte financials performed over time
The total liabilities has grown by 48% YoY but it has contracted by 2.9% from the previous quarter
Veracyte's total assets has increased by 10% YoY
The debt is 96% less than the equity
The equity has grown by 7% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.